Figure 23, NMB (£30,000 per QALY threshold) varying the RR for azithromycin - Cystic Fibrosis - NCBI Bookshelf

Warning: The NCBI web site requires JavaScript to function. more...

Figure 23. NMB (£30,000 per QALY threshold) varying the RR for azithromycin.

Figure 23NMB (£30,000 per QALY threshold) varying the RR for azithromycin

NMB, net monetary benefit at a £30,000 threshold: no treatment, £68,973; prednisolone, £86,283; ibuprofen, £76,867; fluticasone, −£77,603; azithromycin, dependent on the RR

From: Appendix K, Health Economics

Cover of Cystic Fibrosis

Cystic Fibrosis: Diagnosis and management.

NICE Guideline, No. 78.

National Guideline Alliance (UK).

London: National Institute for Health and Care Excellence (NICE); 2017 Oct 25.

Copyright © NICE 2017.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.